Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes
- PMID: 1661736
- DOI: 10.1002/jcb.240470206
Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes
Abstract
Transgenic mice carrying oncogenes present a useful model with which to assess the tissue-specific action of oncogenes. These mice are usually predisposed to a specific type of neoplastic growth. The tumors that arise are usually monoclonal in origin and become only apparent after a variable latency period, suggesting that additional events are required for tumor formation. Identification of these additional events is highly relevant: it might give access to the genes that can synergize with a preselected oncogene in tumorigenesis and could facilitate the identification of the biochemical pathways in which these genes act. Retroviruses can be instrumental in identifying cooperating oncogenes. Proto-oncogene activation or tumor suppressor gene inactivation by insertional mutagenesis is an important mechanism by which the non-acute transforming retroviruses can induce tumors in several species. Owing to the sequence tag provided by the provirus, the relevant proto-oncogene can be directly identified by cloning of the DNA flanking the proviral insertion site. We have exploited this potential of retroviruses by infecting E mu-pim-1 and E mu-myc transgenic mice, which are predisposed to lymphomagenesis, with Moloney murine leukemia virus (MuLV). A strong acceleration of tumor induction ensued upon infection of these mice with MuLV. More importantly, it allowed us to identify a number of additional common insertion sites marking both previously known as well as new (putative) oncogenes. In a significant portion of the tumors more than one oncogene was found to be activated, indicating that within this system the synergistic effect of at least three genes can be established.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.Oncogene. 1995 Nov 2;11(9):1729-36. Oncogene. 1995. PMID: 7478600
-
Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas.EMBO J. 1997 Feb 3;16(3):441-50. doi: 10.1093/emboj/16.3.441. EMBO J. 1997. PMID: 9034327 Free PMC article.
-
Oncogenesis by Moloney murine leukemia virus.Anticancer Res. 1987 Mar-Apr;7(2):171-80. Anticancer Res. 1987. PMID: 3592629
-
Transgenic mice as a means to study synergism between oncogenes.Int J Cancer Suppl. 1989;4:22-5. doi: 10.1002/ijc.2910440706. Int J Cancer Suppl. 1989. PMID: 2681009 Review.
-
The involvement of oncogenes and suppressor genes in human neoplasia.Adv Pediatr. 1987;34:1-44. Adv Pediatr. 1987. PMID: 3318293 Review.
Cited by
-
Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice.PLoS One. 2011;6(7):e22167. doi: 10.1371/journal.pone.0022167. Epub 2011 Jul 25. PLoS One. 2011. PMID: 21799785 Free PMC article.
-
Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.J Virol. 1995 Nov;69(11):7138-46. doi: 10.1128/JVI.69.11.7138-7146.1995. J Virol. 1995. PMID: 7474134 Free PMC article.
-
Evi-5, a common site of retroviral integration in AKXD T-cell lymphomas, maps near Gfi-1 on mouse chromosome 5.J Virol. 1995 Nov;69(11):7132-7. doi: 10.1128/JVI.69.11.7132-7137.1995. J Virol. 1995. PMID: 7474133 Free PMC article.
-
Transgenic and knockout mice in the study of neurodegenerative diseases.J Mol Med (Berl). 1996 Mar;74(3):111-26. doi: 10.1007/BF01575443. J Mol Med (Berl). 1996. PMID: 8846161 Review.
-
Gene therapy in The Netherlands: highlights from the Low Countries.J Gene Med. 2007 Oct;9(10):895-903. doi: 10.1002/jgm.1094. J Gene Med. 2007. PMID: 17721875 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials